Patents by Inventor James Gail Christensen

James Gail Christensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATIONS OF KRAS G12D INHIBITORS WITH PI3Ka INHIBITORS AND RELATED METHODS OF TREATMENT
    Publication number: 20240408098
    Abstract: The present invention relates to combination therapies for treating KRas G12D cancers: in particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a PI3Ka inhibitor and a KRas G12D inhibitor, pharmaceutical compositions comprising a such compositions, kits comprising such compositions and methods of use thereof.
    Type: Application
    Filed: October 4, 2022
    Publication date: December 12, 2024
    Inventors: Jill Hallin, James Gail Christensen, Vickie Bowcut, Peter Olson
  • COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH Pan ErbB FAMILY INHIBITORS
    Publication number: 20240408099
    Abstract: The present invention relates to combination therapies for treating KRas G12D cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a pan ErbB family inhibitor and a KRAS G12D inhibitor of Formula (I), pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.
    Type: Application
    Filed: October 4, 2022
    Publication date: December 12, 2024
    Inventors: Jill Hallin, James Gail Christensen, Vickie Bowcut, Peter Olson
  • COMBINATION THERAPIES USING PRMT5 INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20240398795
    Abstract: Disclosed herein are methods of treating cancer. More specifically, this disclosure provides methods for treating cancer in a subject using compounds that are inhibitors of PRMT5, particularly in combination with a taxane.
    Type: Application
    Filed: October 6, 2022
    Publication date: December 5, 2024
    Inventors: Peter OLSON, Lars Daniel ENGSTROM, James Gail CHRISTENSEN
  • Combination therapies using PRMT5 inhibitors for the treatment of cancer
    Patent number: 12128048
    Abstract: This disclosure relates to methods of treating cancer. This disclosure further relates to treating cancer in a subject with compounds that are inhibitors of PRMT5, particularly in combination with KRASG12C inhibitors.
    Type: Grant
    Filed: April 5, 2022
    Date of Patent: October 29, 2024
    Assignee: Mirati Therapeutics, Inc.
    Inventors: Lars Daniel Engstrom, Peter Olson, James Gail Christensen
  • KRAS G12D INHIBITORS
    Publication number: 20240309020
    Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: April 23, 2024
    Publication date: September 19, 2024
    Inventors: Xiaolun Wang, Aaron Craig Burns, James Gail Christensen, John Michael Ketcham, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith, Shelley Allen, James F. Blake, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Macedonio J. Mejia, Brad Newhouse, Phong Nguyen, Jacob Matthew O'Leary, Spencer Pajk, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P.A. Vigers, Qian Zhao, Dean Russell Kahn, John Gaudino, Michael Christopher Hilton
  • KRAS G12C INHIBITORS
    Publication number: 20240228510
    Abstract: The present invention relates to compounds that inhibit KRas G12C; in particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: April 14, 2022
    Publication date: July 11, 2024
    Inventors: Aaron Craig Burns, James Gail Christensen, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith
  • COMBINATION THERAPIES
    Publication number: 20240156821
    Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a an agent that blocks Programmed Death-1 receptor (PD-1) and Programmed Death Ligand-1 (PD-L1) signaling and a KRAS G12C inhibitor of Formula (I), Formula I-A or Formula I-B, kits comprising the compositions and methods of use therefor.
    Type: Application
    Filed: December 18, 2023
    Publication date: May 16, 2024
    Inventors: David Briere, James Gail Christensen, Peter Olson
  • KRas G12D inhibitors
    Patent number: 11964989
    Abstract: Compounds that inhibit KRas G12D. In particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 20, 2022
    Date of Patent: April 23, 2024
    Assignees: Mirati Therapeutics, Inc., Array BioPharma Inc.
    Inventors: Xiaolun Wang, Aaron Craig Burns, James Gail Christensen, John Michael Ketcham, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith, Shelley Allen, James F. Blake, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Macedonio J. Mejia, Brad Newhouse, Phong Nguyen, Jacob Matthew O'Leary, Spencer Pajk, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P.A. Vigers, Qian Zhao, Dean Russell Kahn, John Gaudino, Michael Christopher Hilton
  • KRAS G12C INHIBITORS
    Publication number: 20240101553
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: August 4, 2023
    Publication date: March 28, 2024
    Inventors: Matthew Arnold MARX, James Gail CHRISTENSEN, Christopher Ronald SMITH, James F. BLAKE, Laurence E. BURGESS, Mark Joseph CHICARELLI, Adam COOK, Jay Bradford FELL, John P. FISCHER, Macedonio J. MEJIA, Martha E. RODRIGUEZ, Pavel SAVECHENKOV, Tony P. TANG, Guy P.A. VIGERS
  • Combination therapies
    Patent number: 11890285
    Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a an agent that blocks Programmed Death-1 receptor (PD-1) and Programmed Death Ligand-1 (PD-L1) signaling and a KRAS G12C inhibitor of Formula (I), Formula I-A or Formula I-B, kits comprising the compositions and methods of use therefor.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: February 6, 2024
    Assignee: Mirati Therapeutics, Inc.
    Inventors: David Briere, James Gail Christensen, Peter Olson
  • METHODS FOR TREATMENT OF LUNG CANCERS
    Publication number: 20230383359
    Abstract: The present invention relates to methods for treatment of lung cancers, in particular non-small cell lung cancer (NSCLC), wherein lung cancers have both a KRAS G12C mutation and an STK11 mutation, with adagrasib (MRTX849).
    Type: Application
    Filed: October 21, 2021
    Publication date: November 30, 2023
    Inventors: James Gail Christensen, Andrew Chi, Thian Kheoh
  • KRAS G12C INHIBITORS
    Publication number: 20230373999
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: October 21, 2022
    Publication date: November 23, 2023
    Inventors: Matthew Arnold MARX, James Gail CHRISTENSEN, Christopher Ronald SMITH, James F. BLAKE, Laurence E. BURGESS, Mark Joseph CHICARELLI, Adam COOK, Jay Bradford FELL, John P. FISCHER, Macedonio J. MEJIA, Martha E. RODRIGUEZ, Pavel SAVECHENKOV, Tony P. TANG, Guy P.A. VIGERS
  • KRAS G12D INHIBITORS
    Publication number: 20230279025
    Abstract: The present invention relates to compounds that inhibit KRas G12D, In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: February 25, 2021
    Publication date: September 7, 2023
    Inventors: Xiaolun Wang, Aaron Craig Burns, James Gail Christensen, John Michael Ketcham, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith, Shelley Allen, James Francis Blake, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Macedonio J. Mejia, Brad Newhouse, Phong Nguyen, Jacob Matthew O'Leary, Spencer Pajk, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P.A. Vigers, Qian Zhao, Dean Russell Kahn, John Gaudino, Michael Christopher Hilton
  • SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS
    Publication number: 20230137025
    Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: August 26, 2022
    Publication date: May 4, 2023
    Inventors: Matthew Arnold MARX, Matthew Randolph LEE, Thomas P. BOBINSKI, Aaron Craig BURNS, Nidhi ARORA, James Gail CHRISTENSEN, John Michael KETCHAM
  • KRAS G12D INHIBITORS
    Publication number: 20230077225
    Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Application
    Filed: July 20, 2022
    Publication date: March 9, 2023
    Inventors: Xiaolun Wang, Aaron Craig Burns, James Gail Christensen, John Michael Ketcham, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith, Shelley Allen, James F. Blake, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Macedonio J. Mejia, Brad Newhouse, Phong Nguyen, Jacob Matthew O'Leary, Spencer Pajk, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P.A. Vigers, Qian Zhao, Dean Russell Kahn, John Gaudino, Michael Christopher Hilton
  • KRas G12C inhibitors
    Patent number: 11548888
    Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: January 10, 2023
    Assignees: Mirati Therapeutics, Inc., Array BioPharma Inc.
    Inventors: Matthew Arnold Marx, James Gail Christensen, Christopher Ronald Smith, John P Fischer, Aaron Craig Burns
  • Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
    Patent number: 11485738
    Abstract: The present invention relates to compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: November 1, 2022
    Assignee: MIRATI THERAPEUTICS, INC.
    Inventors: Matthew Arnold Marx, Matthew Randolph Lee, Thomas P. Bobinski, Aaron Craig Burns, Nidhi Arora, James Gail Christensen, John Michael Ketcham
  • Combination Therapies Using PRMT5 Inhibitors for the Treatment of Cancer
    Publication number: 20220331324
    Abstract: This disclosure relates to methods of treating cancer. This disclosure further relates to treating cancer in a subject with compounds that are inhibitors of PRMT5, particularly in combination with KRASG12C inhibitors.
    Type: Application
    Filed: April 5, 2022
    Publication date: October 20, 2022
    Inventors: Lars Daniel Engstrom, Peter Olson, James Gail Christensen
  • Combination Therapies Using PRMT5 Inhibitors for the Treatment of Cancer
    Publication number: 20220331323
    Abstract: This disclosure relates to methods of treating cancer. This disclosure further relates to treating cancer in a subject with compounds that are inhibitors of PRMT5, particularly in combination with CDK4/6 inhibitors.
    Type: Application
    Filed: April 5, 2022
    Publication date: October 20, 2022
    Inventors: Lars Daniel Engstrom, Peter Olson, James Gail Christensen
  • KRas G12D inhibitors
    Patent number: 11453683
    Abstract: Compounds that inhibit KRas G12D; in particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: September 27, 2022
    Assignees: MIRATI THERAPEUTICS, INC., ARRAY BIOPHARMA INC.
    Inventors: Xiaolun Wang, Aaron Craig Burns, James Gail Christensen, John Michael Ketcham, John David Lawson, Matthew Arnold Marx, Christopher Ronald Smith, Shelley Allen, James F. Blake, Mark Joseph Chicarelli, Joshua Ryan Dahlke, Donghua Dai, Jay Bradford Fell, John Peter Fischer, Macedonio J. Mejia, Brad Newhouse, Phong Nguyen, Jacob Matthew O'Leary, Spencer Pajk, Martha E. Rodriguez, Pavel Savechenkov, Tony P. Tang, Guy P. A. Vigers, Qian Zhao, Dean Russell Kahn, John Gaudino, Michael Christopher Hilton